Clinical Pathway for patients with acquired hemophilia.

This algorithm and case study are meant to raise awareness of common steps for treating acquired hemophilia in the emergency department (ED) setting.^a Review the journey and accompanying patient case study to determine the best way to help your patients.

^aThe provided example is for discussion purposes only and is not intended to represent a recommended algorithm for actual decision making. This example does not constitute guidance for medical advice or treatment.

Clinical Pathway ▾

coagulation disorders code icon

Looking for codes for

coagulation disorders?

Get the diagnosis codes

NovoSevenRT vials and dosing

Need dosing

information?

See recommendations

Find a representative

Have a question? We're

here to help.

Find a representative

Also Available from Novo Nordisk:

Visit website
Prescribing Information

Visit website
Prescribing Information

Visit website
Prescribing Information

Visit website
Prescribing Information

Visit website
Prescribing Information

Visit website
Prescribing Information

Visit website
Prescribing Information

Visit website
Prescribing Information

Selected Important Safety Information

WARNING: THROMBOSIS

Serious arterial and venous thrombotic events following administration of NovoSeven^® RT have been reported
Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven^® RT
Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

Serious arterial and venous thrombotic events following administration of NovoSeven^® RT have been reported
Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven^® RT
Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven^® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven^® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

Thrombosis may occur if NovoSeven^® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information including boxed Warning.

References:

Kruse-Jarres R, Kempton C, Baudo F et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017;92:695–705.
Delgado J et al. Acquired hemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21-35.
Knoebl P, Marco P, Baudo F, et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-631.
Shander A, Walsh CE, Cromwell C. Acquired hemophilia: a rare but life-threatening potential cause of bleeding in the intensive care unit. Intensive Care Med. 2011;37(8):1240-1249.
NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.